Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.
<h4>Introduction</h4>End-stage renal disease (ESRD) strongly associates with cardiovascular disease (CVD) risk. This risk is not completely mitigated by renal replacement therapy. Endothelial dysfunction (ED) and low-grade inflammation (LGI) may contribute to the increased CVD risk. Howe...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0222547 |
id |
doaj-783ee53c2bd44954a79d16e4b0e16d82 |
---|---|
record_format |
Article |
spelling |
doaj-783ee53c2bd44954a79d16e4b0e16d822021-03-04T10:24:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01149e022254710.1371/journal.pone.0222547Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.April C E van GennipNatascha J H BroersKarlien J Ter MeulenBernard CanaudMaarten H L ChristiaansTom CornelisMariëlle A C J GelensMarc M H HermansConstantijn J A M KoningsJeroen B van der NetFrank M van der SandeCasper G SchalkwijkFrank StifftJoris J J M WirtzJeroen P KoomanRemy J H Martens<h4>Introduction</h4>End-stage renal disease (ESRD) strongly associates with cardiovascular disease (CVD) risk. This risk is not completely mitigated by renal replacement therapy. Endothelial dysfunction (ED) and low-grade inflammation (LGI) may contribute to the increased CVD risk. However, data on serum biomarkers of ED and LGI during the transition to renal replacement therapy (dialysis and kidney transplantation) are scarce.<h4>Methods</h4>We compared serum biomarkers of ED and LGI between 36 controls, 43 participants with chronic kidney disease (CKD) stage 5 non-dialysis (CKD5-ND), 20 participants with CKD stage 5 hemodialysis (CKD5-HD) and 14 participants with CKD stage 5 peritoneal dialysis (CKD5-PD). Further, in 34 and 15 participants repeated measurements were available during the first six months following dialysis initiation and kidney transplantation, respectively. Serum biomarkers of ED (sVCAM-1, E-selectin, P-selectin, thrombomodulin, sICAM-1, sICAM-3) and LGI (hs-CRP, SAA, IL-6, IL-8, TNF-α) were measured with a single- or multiplex array detection system based on electro-chemiluminescence technology.<h4>Results</h4>In linear regression analyses adjusted for potential confounders, participants with ESRD had higher levels of most serum biomarkers of ED and LGI than controls. In addition, in CKD5-HD levels of serum biomarkers of ED and LGI were largely similar to those in CKD5-ND. In contrast, in CKD5-PD levels of biomarkers of ED were higher than in CKD5-ND and CKD5-HD. Similarly, in linear mixed model analyses sVCAM-1, thrombomodulin, sICAM-1 and sICAM-3 increased after PD initiation. In contrast, incident HD patients showed an increase in sVCAM-1, P-selectin and TNF-α, but a decline of hs-CRP, SAA and IL-6. Further, following kidney transplantation sVCAM-1, thrombomodulin, sICAM-3 and TNF-α were lower at three months post-transplantation and remained stable in the three months thereafter.<h4>Conclusions</h4>Levels of serum biomarkers of ED and LGI were higher in ESRD as compared with controls. In addition, PD initiation and, less convincingly, HD initiation may increase levels of selected serum biomarkers of ED and LGI on top of uremia per se. In contrast to dialysis, several serum biomarkers of ED and LGI markedly declined following kidney transplantation.https://doi.org/10.1371/journal.pone.0222547 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
April C E van Gennip Natascha J H Broers Karlien J Ter Meulen Bernard Canaud Maarten H L Christiaans Tom Cornelis Mariëlle A C J Gelens Marc M H Hermans Constantijn J A M Konings Jeroen B van der Net Frank M van der Sande Casper G Schalkwijk Frank Stifft Joris J J M Wirtz Jeroen P Kooman Remy J H Martens |
spellingShingle |
April C E van Gennip Natascha J H Broers Karlien J Ter Meulen Bernard Canaud Maarten H L Christiaans Tom Cornelis Mariëlle A C J Gelens Marc M H Hermans Constantijn J A M Konings Jeroen B van der Net Frank M van der Sande Casper G Schalkwijk Frank Stifft Joris J J M Wirtz Jeroen P Kooman Remy J H Martens Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy. PLoS ONE |
author_facet |
April C E van Gennip Natascha J H Broers Karlien J Ter Meulen Bernard Canaud Maarten H L Christiaans Tom Cornelis Mariëlle A C J Gelens Marc M H Hermans Constantijn J A M Konings Jeroen B van der Net Frank M van der Sande Casper G Schalkwijk Frank Stifft Joris J J M Wirtz Jeroen P Kooman Remy J H Martens |
author_sort |
April C E van Gennip |
title |
Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy. |
title_short |
Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy. |
title_full |
Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy. |
title_fullStr |
Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy. |
title_full_unstemmed |
Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy. |
title_sort |
endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
<h4>Introduction</h4>End-stage renal disease (ESRD) strongly associates with cardiovascular disease (CVD) risk. This risk is not completely mitigated by renal replacement therapy. Endothelial dysfunction (ED) and low-grade inflammation (LGI) may contribute to the increased CVD risk. However, data on serum biomarkers of ED and LGI during the transition to renal replacement therapy (dialysis and kidney transplantation) are scarce.<h4>Methods</h4>We compared serum biomarkers of ED and LGI between 36 controls, 43 participants with chronic kidney disease (CKD) stage 5 non-dialysis (CKD5-ND), 20 participants with CKD stage 5 hemodialysis (CKD5-HD) and 14 participants with CKD stage 5 peritoneal dialysis (CKD5-PD). Further, in 34 and 15 participants repeated measurements were available during the first six months following dialysis initiation and kidney transplantation, respectively. Serum biomarkers of ED (sVCAM-1, E-selectin, P-selectin, thrombomodulin, sICAM-1, sICAM-3) and LGI (hs-CRP, SAA, IL-6, IL-8, TNF-α) were measured with a single- or multiplex array detection system based on electro-chemiluminescence technology.<h4>Results</h4>In linear regression analyses adjusted for potential confounders, participants with ESRD had higher levels of most serum biomarkers of ED and LGI than controls. In addition, in CKD5-HD levels of serum biomarkers of ED and LGI were largely similar to those in CKD5-ND. In contrast, in CKD5-PD levels of biomarkers of ED were higher than in CKD5-ND and CKD5-HD. Similarly, in linear mixed model analyses sVCAM-1, thrombomodulin, sICAM-1 and sICAM-3 increased after PD initiation. In contrast, incident HD patients showed an increase in sVCAM-1, P-selectin and TNF-α, but a decline of hs-CRP, SAA and IL-6. Further, following kidney transplantation sVCAM-1, thrombomodulin, sICAM-3 and TNF-α were lower at three months post-transplantation and remained stable in the three months thereafter.<h4>Conclusions</h4>Levels of serum biomarkers of ED and LGI were higher in ESRD as compared with controls. In addition, PD initiation and, less convincingly, HD initiation may increase levels of selected serum biomarkers of ED and LGI on top of uremia per se. In contrast to dialysis, several serum biomarkers of ED and LGI markedly declined following kidney transplantation. |
url |
https://doi.org/10.1371/journal.pone.0222547 |
work_keys_str_mv |
AT aprilcevangennip endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT nataschajhbroers endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT karlienjtermeulen endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT bernardcanaud endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT maartenhlchristiaans endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT tomcornelis endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT marielleacjgelens endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT marcmhhermans endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT constantijnjamkonings endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT jeroenbvandernet endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT frankmvandersande endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT caspergschalkwijk endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT frankstifft endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT jorisjjmwirtz endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT jeroenpkooman endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy AT remyjhmartens endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy |
_version_ |
1714806200793563136 |